(Q33379831)

26 July 2017

title

Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma (English)

1 reference

26 July 2017

1 reference

Howard G Muntz

1

1 reference

26 July 2017

Thomas W Malpass

2

1 reference

26 July 2017

Kathryn F McGonigle

3

1 reference

26 July 2017

Mandy D Robertson

4

1 reference

26 July 2017

Paul L Weiden

5

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

113

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

490-496

1 reference

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

Advanced epithelial ovarian cancer: 1998 consensus statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

The follow-up of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

A phase I and pharmacokinetic study of intraperitoneal topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Intraperitoneal chemotherapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Emerging role of topotecan in front-line treatment of carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

The development of camptothecin analogs in childhood cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Optimal chemotherapy treatment for women with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Serum cystatin C is a better marker of topotecan clearance than serum creatinine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23576

7 January 2021

Identifiers

DOI

10.1002/CNCR.23576

1 reference

26 July 2017

1 reference